Success Story: Our Firm Secured NIW Approval for a Student from Taiwan Through a Strong Case in Biomedical Artificial Intelligence
Client’s Testimonial:
"The lawyers were very professional and had deep understanding of the application process. They were very experienced and framed a strong argument with my case."
On March 14th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Student in the Field of Biomedical Artificial Intelligence (Approval Notice).
General Field: Biomedical Artificial Intelligence
Position at the Time of Case Filing: Student
Country of Origin: Taiwan
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: March 14th, 2026
Processing Time: 3 months, 10 days (Premium Processing Upgrade Requested)
Case Summary:
When preparing this I-140 NIW case, the central task was to show that the client’s work in biomedical artificial intelligence had value far beyond a narrow research setting. The petition presented the client as a professional holding an advanced degree, with an M.T.M., whose proposed endeavor is to continue developing data-driven predictive analytics methods and clinical translational research strategies to improve early detection models and chronic disease management in precision medicine while supporting more accessible healthcare delivery in the United States. That framing was important because it connected the client’s research directly to issues that adjudicators readily recognize as nationally important, including earlier diagnosis, better disease management, and more efficient healthcare systems.
The petition also showed that the client was not advancing a speculative plan. Instead, it tied the proposed endeavor to concrete ongoing work in the field. The client was described as currently employed in a business analyst role, with continuing plans to conduct healthcare data analysis, research clinical and market trends. In NIW cases, this kind of evidence helps demonstrate that the client is not merely interested in the field but is actively positioned to keep moving the work forward.
To support that point, the petition highlighted a compact but meaningful record of achievement. The client had authored 2 peer-reviewed journal articles and 1 patent, and the published work had received 23 citations. Those figures were not presented as automatically sufficient on their own. Rather, the case used them to show that the client had already produced work that others in the field found useful enough to cite and build upon.
The substance of the client’s research also supported the NIW framework. The petition described work on deep learning for brain tumor detection and segmentation, along with machine learning methods for identifying white-coat hypertension and white-coat uncontrolled hypertension. In other words, the record linked the client’s research to better diagnostics, more interpretable models, and more effective clinical decision-making, all of which helped explain why the proposed endeavor had both substantial merit and national importance.
Another effective part of the case was how it demonstrated significance. Rather than relying only on publication totals, the petition pointed to evidence that other researchers had directly used the client’s findings in their own investigations. Taken together, the academic output, citation history, and evidence of real-world utility made the case that the client was well-positioned to continue advancing the proposed endeavor in the United States.
Overall, this approval story shows how a focused NIW petition can succeed by combining a clearly defined biomedical artificial intelligence endeavor, ongoing employment in the field, a credible publication and patent record, and a careful explanation of why the client’s work matters to U.S. healthcare innovation. The result was an approved I-140 NIW case built on a persuasive showing that the client’s contributions could support earlier detection, better chronic disease management, and more accessible precision medicine in the United States.